STERIS plc Announces Director Departure and Officer Changes

Ticker: STE · Form: 8-K · Filed: 2026-04-06T17:02:50-04:00

Sentiment: neutral

Topics: director-departure, officer-appointment, compensation-arrangements

TL;DR

STERIS director Sullivan out, new exec comp plans in effect 3/31.

AI Summary

On April 6, 2026, STERIS plc filed an 8-K report detailing the departure of Director Thomas L. D. Sullivan. The filing also announced the appointment of new directors and changes in officer compensation arrangements, effective March 31, 2026. Specific details regarding the new compensation arrangements were not fully disclosed in the provided excerpt.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Director departures and changes in executive compensation can sometimes indicate underlying issues or strategic shifts that may affect the company's future performance.

Key Players & Entities

FAQ

Who is the departing director mentioned in the filing?

Thomas L. D. Sullivan is the departing director mentioned in the filing.

What is the CIK number for STERIS plc?

The CIK number for STERIS plc is 0001757898.

When was this 8-K filing accepted by the SEC?

This 8-K filing was accepted by the SEC on April 6, 2026, at 17:02:50.

What is the primary item discussed in this 8-K filing?

The primary item discussed is Item 5.02, concerning the departure of directors, election of directors, appointment of officers, and compensatory arrangements of certain officers.

What is the effective date for the compensatory arrangements of certain officers?

The compensatory arrangements of certain officers are effective as of March 31, 2026.

Filing Stats: 593 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2026-04-06 17:02:50

Key Financial Figures

Filing Documents

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 STERIS plc (Exact Name of Registrant as Specified in Charter) Ireland 001-38848 98-1455064 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 70 Sir John Rogerson's Quay , Dublin 2 , Ireland D02 R296 (Address of principal executive offices) Registrant's telephone number, including area code: + 353 1 232 2000 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, $0.001 par value STE New York Stock Exchange 2.700% Senior Notes due 2031 STE/31 New York Stock Exchange 3.750% Senior Notes due 2051 STE/51 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 31, 2026, STERIS plc (the "Company") and Michael J. Tokich, the Company's former Chief Financial Officer, entered into an amendment (the "Amendment") to the Transition Agreement, dated August 5, 2025, between the Company and Mr. Tokich (the "Agreement"). In general, the Agreement governs the compensation and benefits that Mr. Tokich receives for his post-executive employment with the Company. Pursuant to the Amendment, Mr. Tokich's employment with the Company as a senior financial advisor will be extended on a part-time basis from April 1, 2026 through March 31, 2027 (the "Extended Advisor Period"). The Amendment also provides that, during the Extended Advisor Period, Mr. Tokich's annual base salary will be reduced to $60,000, Mr. Tokich will be eligible for a cash bonus at the discretion of the Company's Chief Executive Officer, subject to the approval of the Compensation and Organization Development Committee, and Mr. Tokich will no longer be entitled to benefits under the Company's health and dental plans as well as any life insurance, vacation, disability or other employee benefit plans or programs. Except as described above, the other terms in the Agreement will continue to be in effect through the Extended Advisor Period. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STERIS plc By /s/ J. Adam Zangerle Name: J. Adam Zangerle Title: Senior Vice President, General Counsel & Company Secretary Dated: April 6, 2026

View on Read The Filing